Open Source Drug Discovery. A feasible business model?
Jagadeesh Napa (Assistant Editor of Pharma Focus Asia) has a nice assay on Open Source Drug Discovery and is feasibility as a business model. We are glad that Jagadeesh has named TDI as one of the “major open source initiatives”.
- BROWSE / IN TIMELINE
- « 2008 Target Competition for Neglected Diseases (UC Berkeley)
- » Our TDI kernel has been published!
- BROWSE / IN Article News
- « 2008 Target Competition for Neglected Diseases (UC Berkeley)
- » Our TDI kernel has been published!
COMMENTS / 2 COMMENTS
Mattodd added these pithy words on Mar 09 09 at 11:02 pmInteresting, but there are two statements I don’t understand in the article:
1) “under TDI, IP rights of the drugs discovered would rest with Virtual Pharma, a group of non-profit venture capital firms” Is that right? I think this general idea comes from the original PLoS Med article, but this is not a necessary outcome of TDI.
2) “CSIR is a step ahead as it encourages participation through its incentive scheme”. What incentive scheme? Is CSIR paying people?
clarson added these pithy words on Nov 09 09 at 6:15 pmHi, you probably already have found the answer to your second question, but if not, as I understand it, contributors to CSIR will receive microcredits. Once an individual has accumulated so many microcredits, he/she is eligible for a monetary reward. India’s federal government has already committed $38 million.
SPEAK / ADD YOUR COMMENT
Comments are moderated.
You must be logged in to post a comment.
